Market Place
Sourcing Support
TNF Pharmaceuticals Begins Trading Under New Symbol "TNFA"
24 Jul 2024 //
BUSINESSWIRE
MyMD Pharmaceuticals Rebrands As TNF Pharmaceuticals, Inc
22 Jul 2024 //
BUSINESSWIRE
MyMD Appoints Mitchell Glass As President And Chief Medical Officer
17 Jun 2024 //
BUSINESSWIRE
MyMD Pharmaceuticals Secures Strategic Investments
21 May 2024 //
BUSINESSWIRE
MyMD Regains Compliance with Nasdaq Minimum Bid Price Requirement
05 Mar 2024 //
BUSINESSWIRE
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 2024 //
BUSINESSWIRE
MyMD Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
06 Dec 2023 //
BUSINESSWIRE
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog
19 Oct 2023 //
BUSINESSWIRE
MyMD Pharmaceuticals to Present Phase 2 Data for MYMD-1
04 Oct 2023 //
BUSINESSWIRE
MyMD Pharma to Hold Conference Call Today to Discuss Phase 2 Trial Results
02 Aug 2023 //
BUSINESSWIRE
MyMD`s drug shows promise against age-related inflammation
31 Jul 2023 //
FIERCE BIOTECH
MyMD Provides Dosing Update on Phase 2 Trial of MYMD-1
12 Apr 2023 //
BUSINESSWIRE
MyMD and Charles River Present Positive Data for MYMD-1
20 Mar 2023 //
BUSINESSWIRE
MyMD Joins LOT Network in Effort to Protect Company from Patent Trolls
08 Mar 2023 //
BUSINESSWIRE
MyMD Announces U.S. DEA Determines Supera-CBD is not a Controlled Substance
02 Mar 2023 //
BUSINESSWIRE
MyMD Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data
28 Feb 2023 //
BUSINESSWIRE
MyMD Announces $15 Million Offering with Existing Investors
21 Feb 2023 //
BUSINESSWIRE
MyMD Pharma to Present Data on Oral TNF-a Inhibitor MYMD-1 at BSI Congress 2022
06 Dec 2022 //
BUSINESSWIRE
MyMD Pharma Announces Upcoming Presentation of Late-Breaking Data for MYMD-1
17 Nov 2022 //
BUSINESSWIRE
MyMD Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1
14 Nov 2022 //
BUSINESSWIRE
MyMD Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1
20 Sep 2022 //
BUSINESSWIRE
MyMD Receives Grant From European Patent Office for Supera-CBD Compound
30 Aug 2022 //
BUSINESSWIRE
MyMD Pharma to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1
12 Jul 2022 //
BUSINESSWIRE
MyMD Pharmaceuticals Advances PII Multi-Center Clinical Trial of MYMD-1
21 Jun 2022 //
BUSINESSWIRE
MyMD Pharma Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1
23 Feb 2022 //
BUSINESSWIRE
MyMD Pharma Shows Positive Data for Upcoming Phase 2 Trial of MYMD-1
08 Feb 2022 //
BUSINESSWIRE
MyMD Pharma Announces Issuance of New U.S. Patent Covering MYMD-1
05 Jan 2022 //
BUSINESSWIRE
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation
29 Dec 2021 //
BUSINESSWIRE
Premas, Oravax to Test Their Triple Antigen Oral Vaccine Against Omicron
01 Dec 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering MYMD-1
23 Nov 2021 //
BUSINESSWIRE
Oravax, Genomma Lab Announce Joint Venture for Oral COVID-19 Vaccine
18 Nov 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
12 Nov 2021 //
PRESS RELEASE
MyMD President Chris Chapman Named Medical Honoree of the Year
26 Oct 2021 //
BUSINESSWIRE
MyMD to Detail its Two Upcoming Phase 2 Trials at Benzinga Rising Stars
05 Oct 2021 //
BUSINESSWIRE
MyMD to initiate PII of MYMD-1 for Extending Healthy Lifespan in Q4 2021
13 Sep 2021 //
BUSINESSWIRE
MyMD Pharma to Present its Novel Therapeutic Platforms for Healthy Lifespan
09 Sep 2021 //
BUSINESSWIRE
MyMD Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1
24 Aug 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals to Commence Clinical Trials for Oral COVID-19 Vaccine
10 Aug 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Cannabinoid Compound
10 Aug 2021 //
BUSINESSWIRE
MyMD`s MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19
05 Aug 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals’ MYMD-1 Shows Commonality in Comparative Study
27 Jul 2021 //
PR NEWSWIRE
MyMD Pharmaceuticals Announces New Data from Comparative Study on MYMD-1
08 Jul 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals Announces Issuance of Allowance from United States
22 Apr 2021 //
BUSINESSWIRE
MyMD Announces Issuance of Allowance from US Patent& Trademark Office
22 Apr 2021 //
BUSINESSWIRE
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval
16 Apr 2021 //
BUSINESSWIRE
Akers Announces Shareholder Meeting to Vote on Business Combination with MyMD
22 Mar 2021 //
BUSINESSWIRE
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1
23 Feb 2021 //
BUSINATSSWIRE
